Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Alina Rosinha, Carlos Rabaça, Fernando Calais, João Moreira Pinto, João Vasco Barreira, Ricardo Fernandes, Rodrigo Ramos, Ana Cristina Fialho, José Palma dos Reis*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Downloads

Abstract

Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.

Original languageEnglish
Article number1266369
Number of pages7
JournalFrontiers in Oncology
Volume13
DOIs
Publication statusPublished - 2023

Keywords

  • High-risk
  • identification
  • Non-metastatic castration-resistant prostate cancer
  • Prostate-specific antigen
  • Prostate-specific antigen doubling time
  • Standardization

Fingerprint

Dive into the research topics of 'Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice'. Together they form a unique fingerprint.

Cite this